Futuristics
Long/short equity, biotech, healthcare, small-cap

ViroPharma: Cinryze Shining The Pharma Stock

ViroPharma (VPHM) is an international biopharmaceutical company which develops and commercializes drugs that are used for the treatment for Hereditary Angioedema, or HAE.

The increasing prevalence of HAE provides a tailwind opportunity for the biopharma companies that are producing drugs for this medical condition such as Shire Human Genetic Therapies ,CSL Behring , ViroPharma, Sanquin ,Dyax Corp., Pharming NV , Halozyme Therapeutics and BioCryst. Out of these companies, I believe ViroPharma is well positioned to monetize this opportunity through its Cinryze therapy.

The limited use of first-line steroids on Cinryze and in-house subcutaneous Cinryze would further impact positively on company's growth. I expect ViroPharma to continue adding patients to Cinryze therapy on a continuous...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details